Long-acting beta agonists enhance allergic airway disease

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Knight, John M ^a   Mak, Garbo ^a   Shaw, Joanne ^b   Porter, Paul ^a   McDermott, Catherine ^a   Roberts, Luz ^a   You, Ran ^a   Yuan, Xiaoyi ^a   Millien, Valentine O ^a   Qian, Yuping ^a   Song, Li Zhen ^a   Frazier, Vincent ^a   Kim, Choel ^a   Kim, Jeong Joo ^a   Bond, Richard A ^c   Milner, Joshua D ^d   Zhang, Yuan ^d   Mandal, Pijus K ^e   Luong, Amber ^b   Kheradmand, Farrah ^a   McMurray, John S ^e   Corry, David B ^a   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; FORMOTEROL; PEPTIDOMIMETIC AGENT; PHOSPHOPEPTIDOMIMETIC 242 H; SALMETEROL; STAT6 PROTEIN; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ARRESTIN; CARBAZOLE DERIVATIVE; FORMOTEROL FUMARATE; PROPANOLAMINE DERIVATIVE; RETINA S ANTIGEN; SALBUTAMOL; SALMETEROL XINAFOATE; STAT6 PROTEIN, MOUSE;

ALLERGIC AIRWAY INFLAMMATION; ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NORMAL HUMAN; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS NIGER; ASTHMA; BRONCHOCONSTRICTION; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; KNOCKOUT MOUSE; LUNG; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANIMALS; ANTI-ASTHMATIC AGENTS; ARRESTINS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS NIGER; ASTHMA; BETA-ARRESTINS; BRONCHOCONSTRICTION; CARBAZOLES; DISEASE MODELS, ANIMAL; FEMALE; FORMOTEROL FUMARATE; GENE EXPRESSION; HUMANS; LUNG; MICE; MICE, KNOCKOUT; PEPTIDOMIMETICS; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-2; SALMETEROL XINAFOATE; STAT6 TRANSCRIPTION FACTOR;

EID: 84959432955     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142212     Document Type: Article

References (62)

1. Bezemer GF, Sagar S, van Bergenhenegouwen J, Georgiou NA, Garssen J, Kraneveld AD, et al. Dual role of Toll-like receptors in asthma and chronic obstructive pulmonary disease. Pharmacol Rev. 2012; 64(2):337-58. doi:10.1124/pr.111.004622 PMID: 22407613.
2. Bel EH. Clinical Practice. Mild asthma. N Engl J Med. 2013; 369(6):549-57. doi:10.1056/NEJMcp1214826 PMID: 23924005.
3. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of beta-agonists and the risk of death and near death from asthma [see comments]. N Engl J Med. 1992; 326(8):501-6. PMID: 1346340.
4. Beasley R, Pearce N, Crane J. International trends in asthma mortality. Ciba FoundSymp. 1997; 206:140-50.
5. Beasley R, Pearce N, Crane J, Burgess C. Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? Journal of Allergy & Clinical Immunology. 1999; 104(2 Pt 2): S18-S30.
6. Cazzola M, Page CP, Rogliani P, Matera MG. 2-agonist therapy in lung disease. Am J Respir Crit Care Med. 2013; 187(7):690-6. doi:10.1164/rccm.201209-1739PP PMID: 23348973.
7. Callaerts-Vegh Z, Evans KLJ, Dudekula N, Cuba D, Knoll BJ, Callaerts PFK, et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci U S A. 2004; 101(14):4948-53. PMID: 15069206.
8. Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study. Pulmonary Pharmacology & Therapeutics. 2008; 21(1):134-41.
9. Walker JK, Penn RB, Hanania NA, Dickey BF, Bond RA. New perspectives regarding beta(2) -adrenoceptor ligands in the treatment of asthma. Br J Pharmacol. 2011; 163(1):18-28doi:10.1111/j.1476-5381.2010.01178.x PMID: 21175591.
10. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. Am J Respir Crit Care Med. 2013; 187(12):1308-14. doi:10.1164/rccm.201212-2206OCPMID: 23593932.
11. Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev. 2007; 1.
12. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, et al. beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem. 2006; 281 (2):1261-73. PMID: 16280323.
13. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ. beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem. 2008; 283(9):5669-76. PMID: 18086673.
14. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. 2009; 3.
15. Cates CJ, Cates MJ. Regular treatment with formoterol for chronic asthma: serious adverse events. [Review][Update of Cochrane Database Syst Rev. 2008;(4):CD006923; 18843738]. Cochrane Database of Systematic Reviews. 2012; 4. doi:10.1002/14651858.CD006923.pub3.
16. Cates CJ, Wieland LS, Oleszczuk M, Kew KM. Safety of regular formoterol or salmeterol in adults with asthma: An overview of Cochrane reviews. Cochrane Database Syst Rev. 2014; 2doi:10.1002/14651858.CD010314.pub2.
17. Kudo M, Melton AC, Chen C, Engler MB, Huang KE, Ren X, et al. IL-17A produced by alphabeta T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction. Nat Med. 2012; 18(4):547-54doi:10.1038/nm.2684PMID: 22388091.
18. Corry DB, Irvin CG. Promise and pitfalls in animal-based asthma research: Building a better mousetrap. Immunol Res. 2006; 35(3):279-94. PMID: 17172652.
19. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998; 282(5397):2261-3. PMID: 9856950.
20. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998; 282(5397):2258-61. PMID: 9856949.
21. Goswami S, Angkasekwinai P, Shan M, Greenlee KJ, Barranco WT, Polikepahad S, et al. Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma. Nature Immunology. 2009; 10(5):496-503. doi:10.1038/ni.1719 PMID: 19329997.
22. Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ. A role for TSLP in the development of inflammation in an asthma model. J Exp Med. 2005; 202(6):829-39. PMID: 16172260.
23. Zhou B, Comeau MR, De Smedt T, Liggitt HD, Dahl ME, Lewis DB, et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol. 2005; 6(10):1047-53. PMID: 16142237.
24. Angkasekwinai P, Park H, Wang Y-H, Wang Y-H, Chang SH, Corry DB, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med. 2007; 204(7):1509-17. PMID: 17562814.
25. Millien VO, Lu W, Shaw J, Yuan X, Mak G, Roberts L, et al. Cleavage of fibrinogen by proteinases elicits allergic responses through Toll-like receptor 4. Science. 2013; 341(6147):792-6doi:10.1126/science.1240342PMID: 23950537.
26. Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener-Kronish JP, et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med. 1996; 183(1):109-17. PMID: 8551213.
27. Gavett SH, O'Hearn DJ, Karp CL, Patel EA, Schofield BH, Finkelman FD, et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol. 1997; 272(2 Pt 1):L253-61. PMID: 9124376.
28. Kuperman D, Schofield B, Wills-Karp M, Grusby MJ. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med. 1998; 187(6):939-48. PMID: 9500796.
29. Akimoto T, Numata F, Tamura M, Takata Y. Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med. 1998; 187:1537-42. PMID: 9565645.
30. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011; 365(12):1088-98. doi:10.1056/NEJMoa1106469 PMID: 21812663.
31. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013; 368(26):2455-66. doi:10.1056/NEJMoa1304048 PMID: 23688323.
32. Porter P, Susarla SC, Polikepahad S, Qian Y, Hampton J, Kiss A, et al. Link between allergic asthma and airway mucosal infection suggested by proteinase-secreting household fungi. Mucosal Immunol. 2009; 2(6):504-17. PMID: 19710638. doi:10.1038/mi.2009.102.
33. Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, et al. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem. 2011; 54(10):3549-63. doi:10.1021/jm2000882PMID: 21486047.
34. Zhang Y, Yu X, Ichikawa M, Lyons JJ, Datta S, Lamborn IT, et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol. 2014; 133(5):1400-9. doi:10.1016/j.jaci.2014.02.013PMID: 24589341.
35. Walker JK, Fong AM, Lawson BL, Savov JD, Patel DD, Schwartz DA, et al. Beta-arrestin-2 regulates the development of allergic asthma. J Clin Invest. 2003; 112(4):566-74. Epub 2003/08/20. doi:10.1172/JCI17265112/4/566 [pii]. PMID: 12925697.
36. Nguyen LP, Lin R, Parra S, Omoluabi O, Hanania NA, Tuvim MJ, et al. Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A. 2009; 106(7):2435-40. Epub 2009/01/28. 0810902106 [pii] doi: 10.1073/pnas.0810902106 PMID: 19171883.
37. Mandal PK, Liao WS, McMurray JS. Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3. Organic Letters. 2009; 11(15):3394-7. doi:10.1021/ol9012662 PMID: 19594124.
38. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc Natl Acad Sci U S A. 2001; 98(18):10037-41. PMID: 11517324.
39. Lee SH, Prince JE, Rais M, Kheradmand F, Shardonofsky F, Lu H, et al. Differential requirement for CD18 in T-helper effector homing. Nat Med. 2003; 9(10):1281-6. PMID: 14502280.
40. Polikepahad S, Barranco WT, Porter P, Anderson B, Kheradmand F, Corry DB. A reversible, non-invasive method for airway resistance measurements and bronchoalveolar lavage fluid sampling in mice. J Vis Exp. 2010;38.
41. Kheradmand F, Kiss A, Xu J, Lee SH, Kolattukudy PE, Corry DB. A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J Immunol. 2002; 169(10):5904-11. PMID: 12421974.
42. Shaw JL, Fakhri S, Citardi MJ, Porter PC, Corry DB, Kheradmand F, et al. IL-33-Responsive Innate Lymphoid Cells Are an Important Source of IL-13 in Chronic Rhinosinusitis with Nasal Polyps. American Journal of Respiratory & Critical Care Medicine. 2013; 188(4):432-9. doi:10.1164/rccm.201212-2227OC.
43. Riesenfeld EP, Sullivan MJ, Thompson-Figueroa JA, Haverkamp HC, Lundblad LK, Bates JH, et al. Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease. Respir Res. 2010; 11(22). doi:10.1186/1465-9921-11-22.
44. Lundblad LK, Rinaldi LM, Poynter ME, Riesenfeld EP, Wu M, Aimi S, et al. Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of beta-receptor affinity in murine models of asthma. Respir Res. 2011; 12(27). doi:10.1186/1465-9921-12-27.
45. Booth H, Bish R, Walters J, Whitehead F, Walters EH. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax. 1996; 51(11):1100-4. PMID: 8958892.
46. Corry DB, Grunig G, Hadeiba H, Kurup VP, Warnock ML, Sheppard D, et al. Requirements for allergeninduced airway hyperreactivity in T and B cell-deficient mice. Mol Med. 1998; 4(5):344-55. PMID: 9642684.
47. Rong Y, Arbabian M, Thiriot DS, Seibold A, Clark RB, Ruoho AE. Probing the salmeterol binding site on the beta 2-adrenergic receptor using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol. Biochemistry. 1999; 38(35):11278-86. PMID: 10471277.
48. Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, et al. Adrenaline-activated structure of b2-adrenoceptor stabilized by an engineered nanobody. Nature. 2013; 502:575-9doi:10.1038/nature12572 PMID: 24056936.
49. Barnes PJ. Biochemical basis of asthma therapy. J Biol Chem. 2011; 286(38):32899-905doi:10.1074/jbc.R110.206466 PMID: 21799015.
50. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, et al. beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci U S A. 2003; 100(3):940-5. PMID: 12552097.
51. Kovacs JJ, Hara MR, Davenport CL, Kim J, Lefkowitz RJ. Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell. 2009; 17(4):443-58. doi:10.1016/j.devcel.2009.09.011 PMID: 19853559.
52. Patel PA, Tilley DG, Rockman HA. Physiologic and cardiac roles of beta-arrestins. J Mol Cell Cardiol. 2009; 46(3):300-8doi:10.1016/j.yjmcc.2008.11.015 PMID: 19103204.
53. Liu JJ, Horst R, Katritch V, Stevens RC, Wüthrich K. Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science. 2012; 335:1106-10. doi:10.1126/science.1215802 PMID: 22267580.
54. Hegener O, Prenner L, Runkel F, Baader SL, Kappler J, Haberlein H. Dynamics of beta2-adrenergic receptor-ligand complexes on living cells. Biochemistry. 2004; 43(20):6190-9. PMID: 15147203.
55. Hou J, Schindler U, Henzel WJ, Ho TC, Brasseur M, McKnight SL. An interleukin-4-induced transcription factor: IL-4 Stat. Science. 1994; 265(5179):1701-6. PMID: 8085155.
56. Mionnet C, Buatois V, Kanda A, Milcent V, Fleury S, Lair D, et al. CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med. 2010; 16:1305- 12. doi:10.1038/nm.2253 PMID: 21037587.
57. Nakayama T, Watanabe Y, Oiso N, Higuchi T, Shigeta A, Mizuguchi N, et al. Eotaxin-3/CC chemokine ligand 26 is a functional ligand for CX3CR1. J Immunol. 2010; 185:6472-9. doi:10.4049/jimmunol.0904126PMID: 20974991.
58. Ryan JJ, McReynolds LJ, Keegan A, Wang LH, Garfein E, Rothman P, et al. Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor. Immunity. 1996; 4 (2):123-32. PMID: 8624803.
59. Nino G, Hu A, Grunstein JS, McDonough J, Kreiger PA, Josephson MB, et al. G Protein -subunit signaling mediates airway hyperresponsiveness and inflammation in allergic asthma. PLoS ONE. 2012; 7(2). doi:10.1371/journal.pone.0032078.
60. Duan W, Chan JH, Wong CH, Leung BP, Wong WS. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J Immunol. 2004; 172(11):7053-9. PMID: 15153527.
61. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. 2008; 3.
62. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. 2004; D60:2126-32.